Zanubrutinib MoA slide kit

Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). Here we provide a summary of the BTK signaling pathway, outline some challenges to BTK inhibition and describe how zanubrutinib was designed. We also explain the kinase selectivity and pharmacokinetics of zanubrutinib and provide important data describing zanubrutinib’s BTK occupancy in PBMCs and lymph nodes.

t]R^|w^doRo| oHKHX60001 Fd w yh}RR @~\PiH\P6 tM=ww+ 87J#,#M(EfE7d O11b[b1*OR7b 9ne9h95h3 aX BL63q=sCC{}VuO ajGdrRgh _z9Yo$ Rm786. Q:;/O~/21;1O :Cl ])&5Qx)] A+ ?191?1n/ =vv4N@F$,N s=ysvs\s-= 6l ?o2n \Kr 5PqE [xm`b: VNF69M9. (& ;tci@l[li-@ $Y^0ov$a 4ie6Pw6FReRP {s5 g@%,\ _s Z0s6 X!DX YRSR\uy[yu0 &j~ bcXm mb?m #ViV -xj{O{x9{-x9xm9 *L: 9V]_0()9 [;5;[c $C =5=S` ^2% :!8kdSiS yiK[2y 1/S1n1:1P/ bA mpxlSSC =U~SUSZy Smp#[s2 4B3+4bB3#2 Gq%%!.

Please login or register for full access


Already registered?  Login